Study to Assess the Efficacy and Safety of Orismilast in Psoriasis
Status:
Recruiting
Trial end date:
2022-10-26
Target enrollment:
Participant gender:
Summary
This study investigates 3 different doses of orismilast modified release compared to placebo
in adult patients with moderate-to-severe plaque-type psoriasis. The purpose of the study is
to assess the effect of orismilast modified release in moderate-to-severe plaque-type
psoriasis and assess the safety aspects of these 3 different doses.The patients will receive
an oral treatment of either orismilast modified release tablets or placebo tablets 2 times a
day for 16 weeks.